Paolo Tarantino on HER2 Testing and T-DXd Prediction
Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, shared the following on LinkedIn:
“Evolution of HER2 testing from discovery (1980s) to the ADC days. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at ESMO24: More data with novel assays coming at ASCO25.
Stay tuned!”
This LinkedIn post from Dr. Tarantino highlights the historical progression of HER2 testing in oncology, emphasizing its increasing importance in the context of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd). He points out the limitations of traditional immunohistochemistry (IHC) in accurately predicting patient outcomes with T-DXd and mentions the development of new quantitative assays to improve this. Data on a specific assay, HS-HER2, was presented at ESMO 2024, with further data on novel assays expected at ASCO 2025. This suggests a dynamic and evolving field focused on refining HER2 testing methodologies to better guide treatment decisions and optimize the use of ADCs.
You can read the full article here
Read More on OncoDaily
Antibody-Drug Conjugates and Their Ocular Effects in Cancer Treatment: Efficacy and Toxicity
Bladder Cancer Treatment: The Game-Changing Role of Antibody-Drug Conjugates (ADCs)
New Paper Alert: New Era of Antibody Drug Conjugates in HER2 Positive Breast Cancer
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023